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no known deleterious effects on cardiac potassium 
channels [lo]. Genetic polymorphism in the meta- 
bolism of terfenadine niight explain elevated serum 
concentrations of both terfenadine and its active 
metabolite, although this seems unlikely. 
In conclusion, in the presence of itraconazole, 
circulating intact terfenadine levels remain high and are 
potentially responsible for severe arrhythmia. The role 
of an increased serum concentration of the acid 
metabolite requires further investigation. 
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In-vitro release of vancomycin and netilmicin from 
bone cement 
To the Editors: 
Despite all efforts, prosthetic infections still occur in 1 
to 2% of cases. Once established, infection can be 
difficult to treat with systeniic antibiotics. Several 
studies have shown that gram-positive bacteria, 
especially Staphylocoicus aiueus, coagulase-negative 
staphylococci, Enterococcus faecalis and Coryne- 
bacteriaceae, are responsible for 71 to 84%) of such 
infections Ill. 
In the management of infected joint implants, 
revision arthroplasty with the use of antibiotic-loaded 
acrylic cement (ALAC) has proven to be superior to 
other methods of currently available treatment 121. 
Furthermore, ALAC is a useful adjunct in the 
nianagenient of chronic osteomyelitis and in the 
prevention of recurrent osteoniyelitis after an initial 
attack [3].  Increasing antibiotic resistance of bacteria 
that infect prosthetic joints has stimulated interest in 
the incorporation of more effective antiniicrobial 
agents into acrylic cement. Vanconiycin is effective 
against all staphylococci, and aniinoglycosides have a 
wider spectrum of activity against gram-negative 
bacteria [4]. 
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Considering their broad antibacterial effects against 
both gram-positive and gram-negative bacteria, a study 
of the in-vitro elution of vancomycin and netilmicin 
from bone cement was carried out. 
A prospective in-vitro quantification was per- 
formed to measure the elution of vancomycin and 
netilmicin from bone cement. Vancomycin (500 mg) 
and netilmicin (250 mg) were admixed with 10 g of 
polymethylmethacrylate (PMMA) copolymer powder, 
alone and in combination, prior to the addition of the 
liquid polymer. This was followed, according to the 
manufacturer's specifications, by the addition of 5 mL 
of liquid methylmethacrylate. An exothermic poly- 
merization reaction occurred, yielding a liquid cement 
that solidified over a period of 10 min at room 
temperature under aseptic conditions. From the poly- 
merized cement, uniform cylindrical disks 6 m m  in 
diameter, 9 mm thick and weighing approximately 
500 mg were prepared. Each disk contained 25 mg of 
vancomycin and 12.5 mg of netilmicin alone or in 
combination. The disks were incubated in 10 mL 
tripticase soy broth (TSB) and human plasma at 36OC. 
Antibiotic concentrations were assayed by fluorescense 
polarization immunoassay (TDx, Abbott Laboratories, 
North Chicago, IL) on day 2 and weekly, then replaced 
and retested, for a period of 12 weeks. The lowest 
measurable level of drug concentration was defined as 
that which could be distinguished from 0 with 
95% confidence; this was determined as 2.0 mg/L for 
vancomycin and 0.09 mg/L for netilmicin [ 5 ] .  
To compare the persistence of antibacterial activity 
around the ALAC disks, 1 mL of TSB or plasma was 
mixed with lo5 CFU/mL of a clinical isolate of 
S. aureus. The density of S. aureus suspension was 
determined spectrophotometrically and, subsequently, 
100 pL of the suspension was transferred onto a TSB 
agar plate. After incubation at 36" C for 18 h, the plates 
Table 1 Antibiotic concentrations released from antibiotic- 
loaded bone cement in tripticase soy broth (mg/L) 
Time Vancomycin Netilmicin Vancomycinfnetilmicin 
Day 2 50.30 46.80 74.52 37.73 
Week 1 54.40 49.60 64.85 39.20 
Week 2 6.02 1.58 8.03 1.79 
Week 3 4.49 0.54 3.45 0.75 
Week 4 3.58 0.50 1.62 0.49 
Week 5 2.79 0.40 1.52 0.31 
Week 6 1.88 0.25 1 .so 0.31 
Week 7 1.66 0.20 1.25 0.25 
Week 8 1.45 0.20 1.20 0.25 
Week 9 1.20 0.15 1 .00 0.20 
Week 10 1.00 0.10 0.80 0.15 
Week 11 0.70 0.09 0.60 0.10 
Week 12 0.60 - 0.60 - 
were examined for bacterial gowth. Between-group 
comparisons were made by Mann-Whitney Utest and 
p < 0.05 was considered significant. 
The in-vitro antibacterial activity of vancomycin 
and netilmicin, alone and in combination, in ALAC 
was assessed. All determinants were analyzed in 
duplicate (in TSB and in plasma). There was no 
significant difference in levels of netilmicin and 
vancomycin in either media samples. Antibiotic 
concentrations in TSB were higher than in plasma, but 
this was not statistically significant. Similarly, no 
differences were observed in weekly vancomycin and 
netilmicin levels in either TSB (Table 1) or plasma, 
alone or in combination. The release of vancomycin 
and netilmicin in combination did not differ from the 
release of each drug alone. 
These data indicate that the in-vitro release of 
neither parent antibiotic is reduced when mixed in 
cement. Vancomycin was detected in the test media 
during all 12 weeks of the study whereas netilmicin was 
detected for only 11 weeks of the study. Although 
initial rapid decreases in antibiotic concentration were 
seen during leaching from the cement, the antibacterial 
activity of vancomycin and netilmicin continued for 6 
weeks and 3 weeks, respectively, during the monitoring 
period. 
O n  the basis of the present and previous studies 
[6-81, all of the antibiotics tested remained stable 
throughout the polymerization process of the cement. 
Use of such antibiotic-cement mixtures in clinical 
practice appears to be effective in preventing prosthetic 
infections and, in addition, antibiotic-loaded PMMA 
cement may have a clinical role in the treatment of 
musculoskeletal sepsis caused by gram-positive and 
gram-negative bacteria, particularly in the presence of 
organisms resistant to the usual antibiotic agents. 
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Thrice-weekly maintenance therapy for 
cytomegalovirus retinitis in patients with acquired 
immunodeficiency syndrome (AIDS) 
To the Editors: 
Cytomegalovirus (CMV) retinitis is the most common 
localization of CMV disease in patients with acquired 
imniunodeficiency syndrome (AIDS) and is, in fact, the 
most frequent ocular opportunistic infection, often 
leading to a partial or total loss of vision [I ] .  Induction 
treatment for CMV disease is relatively well stan- 
dardized (2 to 3 weeks of daily intravenous ganciclovir 
or foscarnet) and able to control the progression of the 
retinitis in approximately 60 to 80% of cases [2,3]. With- 
out maintenance therapy, the relapse rate approaches 
100% within 3 to 6 weeks. Even with maintenance 
therapy with ganciclovir (5 mg/kg/day) or foscarnet 
(120 nig/kg/day) daily for 5 daydweek, 50% of 
patients relapse after a median time of 8 to 16 weeks 
[4,5]. It has been suggested that doubling the dose of 
ganciclovir (to 10 nig/kg/day), but with thrice-weekly 
administration, may be as effective as the standard 
dosage of 5 days/week [6,7]. To follow is our report of 
the results of an open, prospective, clinical study of 
maintenance therapy, using the thrice-weekly 
approach, for CMV retinitis in AIDS patients. 
A total of 69 human immunodeficiency virus 
(HIV)-infected adults diagnosed with CMV disease 
between May 1988 and December 1993 were eligible 
for inclusion in the study. Those who had CMV 
retinitis (M = 57), with or without other localizations, 
were given at least 2 weeks of intensive induction 
therapy with eithcr intravenous ganciclovir (5 ing/kg 
every 12 h), foscarnet (60 mg/kg every 8 h) cir both. 
O f  these 57 patients, 33 successfully completed the 
induction treatment, gave their conscnt to receive 
intravenous maintenance therapy thrice weekly and 
were included in the study. Maintenance therapy was 
started with either ganciclovir (10 mg/kg/day) or 
foscarnet (1 00 nig/kg/day) or both, every Monday, 
Wednesday and Friday, for a mean period of 19 
(range 6 to 78) weeks. The crude relapse rate was 51% 
(17/33) and the crude mortality rate was 66%) (22/33). 
Altogether, 27 patients received ganciclovir (1 4 relapses, 
28 deaths), four received foscarnet (two relapses, two 
deaths), and two patients received both (one relapse, 
two deaths). The time to relapse of CMV retinitis, time 
to death or relapse and time to death are shown in 
Figure 3 .  The median time to relapse was 18 weeks, 
the median survival time free of CMV retinitis was 14 
weeks and the median survival time was 34 weeks. 
Neutropenia occurred in eight patients (24%,), seven 
receiving ganciclovir and one receiving foscarnet, and 
anemia occurred in two patients (6%,), both of whom 
were receiving ganciclovir. No changes in therapy were 
required. The neutropenia was con trolled using granulo- 
cyte colony-stimulating factor and the anemia with 
blood transfusion when required. 
Treatment with either drug improved median 
survival time from the time of CMV diagnosis to 6 to 
8 months to almost 1 year in those responding to anti- 
CMV treatment. Maintenance therapy i q  mandatory to 
delay relapse and progression to blindness. The  median 
time to relapse has been reported to range from 2 to 4 
weeks without maintenance therapy and from 8 to 19 
weeks with daily or 5 days/week maintenance therapy 
[4,5]. Both ganciclovir and foscarnet appear to be 
equally effective in preventing relapses, although in at 
least one study, foscarnet significantly increased survival 
time (by around 4 months) coinpared with ganciclovir 
[4). Hall and colleagues [6] and Ganveg and coworkers 
[7] have reported that a total weekly dose of 30 mg/kg 
of ganciclovir, distributed in three, five or seven doses, 
has similar efficacy in preventing relapses. Our results 
are in agreement with these studies and emphasize that 
the thrice-weekly approach does not appear to be 
worse in ternis of survival. Ganciclovir therapy is often 
complicated by severe neutropenia, thereby requiring 
temporary or permanent discontinuation or niodifica- 
tion of dosage in a t  least 25% of patients. In our study, 
eight (24%) of 29 patients developed moderate neutro- 
penia that did not require discontinuation of therapy. 
Thus, the toxicity rate was similar to that seen with 
standard therapy (5 nig/kg/day for 5 days/week). 
At present, oral ganciclovir i s  being evaluated as 
